{
  "symbol": "BIIB",
  "year": 2024,
  "period": "Q1",
  "competition_summary": [
    {
      "competitor": "Reata",
      "mentions": 58,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "3 Table of Contents \u2022",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "IRA",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Biogen Inc.",
      "mentions": 12,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "MabThera",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "TYSABRI\u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Biogen",
      "mentions": 20,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "BENEPALI",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "FLIXABI",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "FUMADERM",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "IMRALDI",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "TOFIDENCE",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "COLUMVI\u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "FAMPYRA",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "LEQEMBI\u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ZURZUVAE",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Share Repurchase Program Board of Directors",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Omnibus Equity Plan Biogen Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ESPP Biogen Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AbbVie AbbVie Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Acorda Acorda Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ALS Amyotrophic Lateral",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "CHMP Committee for Medicinal Products for Human Use CISA Cybersecurity and",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Infrastructure Security Agency",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "CJEU Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the European Union",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "CLO",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Convergence Pharmaceuticals Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Response Letter CROs Contract Research Organizations DEA Drug Enforcement Agency",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Denali Therapeutics Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Plan Biogen Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Non-Employee Directors",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Equity Plan District Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "District Court",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "EC European Commission Eisai Eisai Co.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "EMA European Medicines Agency",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "EPO European Patent Office",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "E.U. European Union FA Friedreich's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Ataxia FASB Financial Accounting Standards Board",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "FDA U.S. Food and Drug Administration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "FSS Federal Supply",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Humana Humana Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Research and Development Ionis Ionis Pharmaceuticals Inc. IRA Inflation Reduction Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "MDD",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Mylan Ireland Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "NCD National Coverage Decision NDA New Drug Application",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AG NMPA National Medicinal Products Administration OECD Organization for Economic Co-operation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Development ODD Orphan Drug Designation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Reata Pharmaceuticals, Inc.",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Samsung Bioepis Co.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Samsung BioLogics Samsung BioLogics Co.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Sangamo Sangamo Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "SEC U.S. Securities and Exchange Commission SG&A Selling",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Survival Motor Neuron SOD1 Superoxide Dismutase 1 SWISSMEDIC Swiss Agency",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Therapeutic Products TBA Technical Boards of Appeal Transition Toll Tax",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Diluted",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Contents BIOGEN INC.",
      "mentions": 10,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "9 Table of Contents BIOGEN INC.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "928.6 Investments",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "EQUITY",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Taxes",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Treasury",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Samsung Bioepis",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Total Biogen Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "38.7 Issuance",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
      "mentions": 38,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Significant Accounting Policies References",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Business Overview Biogen",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "SMA",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ALS",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "TECFIDERA",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "VUMERITY",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AVONEX",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "TYSABRI",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Eisai",
      "mentions": 12,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "PPD",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "non-Hodgkin's",
      "mentions": 11,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "CLL",
      "mentions": 10,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "PPMS",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "RMS",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "LUNSUMIO",
      "mentions": 17,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "COLUMVI",
      "mentions": 9,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Genentech",
      "mentions": 14,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Roche Group",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AMR",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "PMN",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "HI-Bio",
      "mentions": 12,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "HUMIRA",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "BYOOVIZ",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Consolidated Financial Statements",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "FASB",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Climate-Related Disclosures",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "SEC",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "CODM",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Antibody-Mediated Rejection",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Immunoglobulin A Nephropathy (IgAN",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Breakthrough Therapy Designation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ODD",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "FDA",
      "mentions": 11,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Business Combinations",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "izastobart/HIB210",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Goodwill 256.5 Total",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Allocations of Purchase Price",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "QALSODY",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Term Loan",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Indebtedness",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Acquisition Date",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Blackstone",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "E.U.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Samsung BioLogics",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "PRV",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Severance Costs Accelerated Depreciation",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Reata Integration Following",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Restructuring Reserve Charges",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Total Fumarate",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "95.4 125.4 220.8",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "926.5 Total",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "38.3 Total",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Contract Manufacturing Revenue Contract",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "LEQEMBI",
      "mentions": 20,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Finished",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Goodwill Intangible Assets Intangible",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Completed Technology Completed",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ac",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Sangamo",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Fair Value Valuation Technique Significant Unobservable Input(s",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Level",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Fair Value Carrying Value Fair Value Carrying Value Current",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "610.7 Total",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Marketable Debt Securities",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Denali",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AOCI",
      "mentions": 10,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Effectiveness Testing",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "0.3 Investments",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "11.6 Liability",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Plant and Equipment Property",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Solothurn",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Switzerland Manufacturing Facility",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "GMP",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "SWISSMEDIC",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Term Loan Credit Agreement In",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Equity Share Repurchases",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Board of Directors",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Share Repurchase Program",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Cash Flow Hedges",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Pension Benefit Obligation",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AOCI 5.2",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AOCI 13.4",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "AOCI Income Statement Location",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Share-Based Payments Share",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ESPP",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "IRS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Consolidated Financial",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Liabilities",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Roche Group",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "The Roche Group",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Roche",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the First Threshold Date",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "First Threshold Date",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Second Threshold Date",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the U.S. Outside",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the LEQEMBI Collaboration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "LEQEMBI Collaboration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "95.5 Amounts",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "UCB",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "SLE",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "46 Table of Contents BIOGEN INC.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "DEA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "CRL",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "NDA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Sage",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "LRRK2",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "LRRK2 Collaboration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Denali's Transport Vehicle",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ATV",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Transport Vehicle",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the LRRK2 Collaboration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Samsung Bioepis Co., Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Development and Commercialization Agreement",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Variable Interest Entities Consolidated Variable Interest",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Neurimmune SubOne AG Beginning",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the 49 Table of Contents BIOGEN INC.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Contingencies Securities Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the District Court",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Nadia Shash",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Oklahoma Firefighters Pension and Retirement System",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Securities Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Board of Directors",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "The Booth Family Trust",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Wang",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Securities Exchange Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "IMRALDI Patent Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Technical Boards of Appeal",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the European Patent Office",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Fresenius Kabi Deutschland GmbH's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Fresenius Kabi's",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Biogen France SAS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Tribunal de Grande Instance de Paris",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the D\u00fcsseldorf Regional Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Higher Regional Court of D\u00fcsseldorf",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Shareholder Representative Services LLC",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the High Court of Justice of England",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Humana Patient Assistance Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Humana",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the United States Court of Appeals",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the First Circuit",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Genentech Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Genentech, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Lender Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "BioPharma Credit PLC",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "BPCR Limited Partnership",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "BioPharma Credit Investments V (Master",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Supreme Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the State of New York",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "City Council of Baltimore",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Teamsters Local 237 Welfare Fund",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Teamsters Local 237",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Retirees' Benefit Fund",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "DOJ",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "The Italian Competition Authority",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Biosimilar",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Sandoz Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Sandoz",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Polpharma Biologics S.A.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Biologics Price Competition and Innovation Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Annulment Proceedings",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the General Court",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "EMA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Hatch-Waxman Act Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "VUMERITY Orange-Book Listed Patents",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "VUMERITY Orange-Book",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Drug Price Competition and Patent Term Restoration Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the Hatch-Waxman Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "the U.S.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "Zydus Worldwide",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "MANAGEMENT'S",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as "
    }
  ]
}